{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:23:18Z","timestamp":1754162598095,"version":"3.41.2"},"reference-count":42,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.14974","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:17:51Z","timestamp":1741594671000},"page":"1-15","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy outcomes of delta\u2011like ligand 3 inhibitors for the treatment of solid tumors: A systematic review and single\u2011arm meta\u2011analysis"],"prefix":"10.3892","volume":"29","author":[{"given":"Yaxu","family":"Su","sequence":"first","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tongwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hengchang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulu","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dehong","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pizhou County People's Hospital, Xuzhou, Jiangsu 221399, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Pizhou County People's Hospital, Xuzhou, Jiangsu 221399, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Xin","sequence":"additional","affiliation":[{"name":"Department of Radiation, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"key20250730121603_b1-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/nrg3272","article-title":"The Notch signalling system: Recent insights into the complexity of a conserved pathway","volume":"13","author":"Guruharsha","year":"2012","journal-title":"Nat Rev Genet"},{"key":"key20250730121603_b2-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1038\/nrm.2016.94","article-title":"Notch signalling in context","volume":"17","author":"Bray","year":"2016","journal-title":"Nat Rev Mol Cell Bio"},{"key":"key20250730121603_b3-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.ccell.2018.07.009","article-title":"Notch signaling in the tumor microenvironment","volume":"34","author":"Meurette","year":"2018","journal-title":"Cancer Cell"},{"key":"key20250730121603_b4-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nrc1186","article-title":"The role of Notch in tumorigenesis: Oncogene or tumour suppressor?","volume":"3","author":"Radtke","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"key20250730121603_b5-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/hmg\/ddq529","article-title":"Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis","volume":"20","author":"Chapman","year":"2011","journal-title":"Hum Mol Genet"},{"key":"key20250730121603_b6-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/nrclinonc.2017.71","article-title":"Unravelling the biology of SCLC: Implications for therapy","volume":"14","author":"Sabari","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20250730121603_b7-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"key20250730121603_b8-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","article-title":"DLL3 as an emerging target for the treatment of neuroendocrine neoplasms","volume":"27","author":"Yao","year":"2022","journal-title":"Oncologist"},{"key":"key20250730121603_b9-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: An emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol Oncol"},{"key":"key20250730121603_b10-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20250730121603_b11-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20250730121603_b12-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S8582","DOI":"10.1200\/JCO.2023.41.16_suppl.8582","article-title":"Tarlatamab in small cell lung cancer (SCLC): Safety and efficacy analyzed by baseline brain metastasis","volume":"41","author":"Champiat","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20250730121603_b13-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"New Engl J Med"},{"key":"key20250730121603_b14-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S486","DOI":"10.1016\/j.annonc.2023.09.1884","article-title":"698P Interim results from a phase I\/II study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)","volume":"34","author":"Choudhury","year":"2023","journal-title":"Ann Oncol"},{"key":"key20250730121603_b15-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S8510","DOI":"10.1200\/JCO.2021.39.15_suppl.8510","article-title":"Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC)","volume":"39","author":"Owonikoko","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20250730121603_b16-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jtho.2023.09.026","article-title":"OA01.05 Phase I dose escalation trial of the DLL3\/CD3 Igg-like T cell engager BI 764532 in patients with DLL3+ tumors: Focus on SCLC","volume":"18","author":"Wermke","year":"2023","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b17-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: Results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b18-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.jtho.2021.03.012","article-title":"Rovalpituzumab tesirine as a maintenance therapy after first-line platinum-based chemotherapy in patients with extensive-stage-SCLC: Results from the phase 3 MERU study","volume":"16","author":"Johnson","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b19-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"key20250730121603_b20-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-19-1133","article-title":"Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed\/refractory small-cell lung cancer: Results from the phase II TRINITY study","volume":"25","author":"Morgensztern","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20250730121603_b21-ol-29-5-14974","article-title":"DLL3-targeting agents are poised to fill unmet needs in SCLC","volume":"24","author":"Lovely","year":"2023","journal-title":"Oncol Live\u00ae"},{"key":"key20250730121603_b22-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1186\/s12967-024-05568-y","article-title":"DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models","volume":"22","author":"Lin","year":"2024","journal-title":"J Transl Med"},{"key":"key20250730121603_b23-ol-29-5-14974","article-title":"Practical management of adverse events in patients receiving tarlatamab, a DLL3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","author":"Sands","year":"2024","journal-title":"medRxiv"},{"key":"key20250730121603_b24-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1200\/JCO.1999.17.2.658","article-title":"Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer","volume":"17","author":"von Pawel","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20250730121603_b25-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.3-1-4","article-title":"Clinical guidelines for managing topotecan-related hematologic toxicity","volume":"3","author":"Armstrong","year":"1998","journal-title":"Oncologist"},{"key":"key20250730121603_b26-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"1504139","DOI":"10.3389\/fonc.2024.1504139","article-title":"Advances in DLL3-targeted therapies for small cell lung cancer: Challenges, opportunities, and future directions","volume":"14","author":"Ding","year":"2024","journal-title":"Front Oncol"},{"key":"key20250730121603_b27-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1111\/1759-7714.13574","article-title":"DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC","volume":"11","author":"Ogawa","year":"2020","journal-title":"Thorac Cancer"},{"key":"key20250730121603_b28-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy targeting delta-like ligand 3 in small cell lung cancer exhibits antitumor efficacy with low toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20250730121603_b29-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S5012","DOI":"10.1200\/JCO.2024.42.16_suppl.5012","article-title":"Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)","volume":"42","author":"Aggarwal","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20250730121603_b30-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"428","DOI":"10.4103\/1735-5362.350243","article-title":"Design of two immunotoxins based rovalpituzumab antibody against DLL3 receptor; a promising potential opportunity","volume":"17","author":"Ataee","year":"2022","journal-title":"Res Pharm Sci"},{"key":"key20250730121603_b31-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41698-021-00214-y","article-title":"A phase I\/II study of rovalpituzumab tesirine in delta-like 3-expressing, advanced solid tumors","volume":"5","author":"Mansfield","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"key20250730121603_b32-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S260","DOI":"10.1016\/j.jtho.2016.11.252","article-title":"OA05.03 Single-agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC), in small-cell lung cancer (SCLC)","volume":"12","author":"Spigel","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b33-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.ctarc.2021.100405","article-title":"Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer","volume":"28","author":"Calvo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"key20250730121603_b34-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.jtho.2022.07.062","article-title":"OA12.05 phase 1 updated exploration and first expansion data for DLL3-targeted T-cell engager tarlatamab in small cell lung cancer","volume":"17","author":"Borghaei","year":"2022","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b35-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.lungcan.2019.07.025","article-title":"Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer","volume":"135","author":"Udagawa","year":"2019","journal-title":"Lung Cancer"},{"key":"key20250730121603_b36-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S1664","DOI":"10.1016\/j.annonc.2023.10.587","article-title":"508MO Tarlatamab for patients (pts) with previously treated small cell lung cancer (SCLC): Primary analysis of the phase II DeLLphi-301 study","volume":"34","author":"Paz-Ares","year":"2023","journal-title":"Ann Oncol"},{"key":"key20250730121603_b37-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"key20250730121603_b38-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S712","DOI":"10.1016\/S0959-8049(16)31931-1","article-title":"7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC)","volume":"51","author":"Pietanza","year":"2015","journal-title":"Eur J Cancer"},{"key":"key20250730121603_b39-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","article-title":"A phase 1\u20132 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC","volume":"16","author":"Malhotra","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b40-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S126","DOI":"10.1016\/j.jtho.2021.01.313","article-title":"OA11.03 A phase 1 study of AMG 757, half-life extended bispecific T-cell engager (BiTE\u00ae)Immune therapy against DLL3, in SCLC","volume":"16","author":"Owonikoko","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20250730121603_b41-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S100259","DOI":"10.1016\/j.iotech.2022.100259","article-title":"147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer","volume":"16","author":"Champiat","year":"2022","journal-title":"Immun Oncol Technol"},{"key":"key20250730121603_b42-ol-29-5-14974","doi-asserted-by":"publisher","first-page":"S1495","DOI":"10.1016\/j.annonc.2023.10.210","article-title":"75MO Phase I trial of the DLL3\/CD3 IgG-like T cell engager BI 764532 in patients (pts) with DLL3+ tumors: Focus on Asian pts","volume":"34","author":"Kuboki","year":"2023","journal-title":"Ann Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:16:08Z","timestamp":1753866968000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.14974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.14974","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"type":"print","value":"1792-1074"},{"type":"electronic","value":"1792-1082"}],"subject":[],"published":{"date-parts":[[2025,3,10]]}}}